Blueprint Prepares To Take On Novartis In Advanced Systemic Mastocytosis
Company To Initially Target 70 Cancer Centers
Executive Summary
The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.
You may also be interested in...
Blueprint’s Evolution On Its Path To Financial Sustainability
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.
Blueprint’s Ayvakit Mastocytosis Results Raise Commercial Uncertainty
The Phase III PIONEER study in indolent systemic mastocytosis met the primary endpoint, but the magnitude of benefit came up short of analysts’ expectations.
Blueprint May Corner EGFR Exon Mutated Lung Cancer Market With Lengo Buyout
Lengo’s preclinical LNG-451, along with Blueprint’s BLU-945 and BLU-701, could create a portfolio of therapies covering 97% of non-small cell lung cancer cases involving EGFR exon mutations.